Integral Diagnostics completes merger

Integral Diagnostics (ASX:IDX) has successfully completed a merger with Capitol Health (ASX:CAJ). The merger was finalized as of December 20, 2024. Capitol shareholders received 0.12849 Integral shares per Capitol share. The new Integral shares will commence trading on the ASX from December 23, 2024.

Overview of merger and future plans

Integral Diagnostics (ASX:IDX) has finalized its merger with Capitol Health, enhancing its market presence in Australasia. Eligible Capitol shareholders are to receive Integral shares, which will begin trading on December 23, 2024. With the merger, Integral has also restructured its debt, securing $450 million in committed facilities with an option for an additional $200 million. Two former Capitol Directors, Laura McBain and Dr. Kevin Shaw, have joined Integral's Board to aid in the integration process. Capitol Health is set to be delisted from the ASX. This strategic merger aims to expand Integral's operational scale and financial robustness.

Executive commentary on merger

We are pleased to announce the successful completion of our merger with Capitol Health. This strategic move not only strengthens our position in the market but also enhances our service capabilities and financial standing. We look forward to integrating Capitol's expertise with our operations to deliver superior outcomes for our stakeholders.